CBD Life Sciences, Inc. Unveils Groundbreaking Nutritional Supplement Infused With Mushroom Extracts, Set to Drive Revenue and Revolutionize Wellness
Projected to increase company revenue by 20% in the first year, capitalizing on the booming $18 billion wellness market.
SCOTTSDALE, AZ / ACCESSWIRE / September 17, 2024 / CBD Life Sciences, Inc. (CBDL), an innovative leader in the CBD wellness industry, is set to launch a cutting-edge nutritional supplement powder designed to harness the powerful health benefits of natural ingredients. This new supplement contains a proprietary blend of reishi mushroom extract, lion's mane mushroom extract, and ashwagandha root extract, offering an integrated approach to wellness by reducing stress, supporting brain health, and enhancing the immune system.
Recent studies highlight the effectiveness of reishi extract, not only in boosting the immune system but also in slowing or stopping tumor growth, a feature that positions this product as an essential addition to the wellness market. The blend of lion's mane extract and ashwagandha root provides additional cognitive support and anti-inflammatory benefits, making it an all-around solution for physical and mental well-being.
Unrivaled Benefits of Key Ingredients:
Reishi Mushroom Extract: Renowned for its immune-boosting and anti-cancer properties, research suggests it can slow tumor growth, making it one of the most potent natural supplements available today.
Lion's Mane Mushroom Extract: Known for supporting brain health, lion's mane helps to enhance cognitive function and promote nerve regeneration, ideal for those seeking long-term mental clarity.
Ashwagandha Root Extract: Widely celebrated for reducing stress and its anti-inflammatory effects, ashwagandha contributes to overall mental health and physical recovery.
Revenue Projections & Market Potential
With the global supplement market experiencing rapid growth, the introduction of this new product is projected to significantly boost CBD Life Sciences, Inc.'s annual revenue. Analysts expect the market for mushroom-infused supplements to reach $18 billion by 2028, and with the unique blend of ingredients in this product, CBD Life Sciences, Inc. is poised to capture a substantial portion of that market. This launch is expected to drive a revenue increase of 20% within the first year, positioning the company at the forefront of the wellness supplement industry.
A Vision for the Future
Lisa Nelson, President and CEO of CBD Life Sciences, Inc., stated, "We are incredibly excited to bring this innovative product to the market. With the growing demand for natural, scientifically backed health solutions, we believe this supplement will be a game-changer, not only for our company but for the health-conscious consumers we serve."
About CBD Life Sciences, Inc.
The CBD Vault Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. The CBD Vault has developed and is retailing/wholesale a full line of cannabidiol based & organic products including, Delta 8 & 10 Gummy's, Full Spectrum Tinctures & Gummy's, Pain Cream, Roll-on's, Salve, Full Pet Line, Pre-Rolls, Full Line of Spa Products, Sleep & Anxiety Edibles. The CBD Vault's products can be viewed and purchased on the Company's website www.thecbdvault.com.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: [email protected]
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
[email protected]
4802091720
Contact Information
Lisa Nelson
CEO
[email protected]
4802091720
Related Images
|
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com